drugset / Trial / NCT01984489
Efficacy and Safety Study of SHR117887 in Combination With Metformin in Patients With Type 2 Diabetes
RandomizedParallel-groupQuadruple-blindTreatment
Summary
SHR117887 is a new dipeptidyl peptidase(DPP)-4 inhibitor. This study aims to evaluate the efficacy and safety of SHR117887 in combination therapy with Metformin in patients with Type 2 Diabetes in Metformin monotherapy Who have Inadequate Glycemic Control
Timeline
- Start
- 2012-06
- Primary completion
- 2013-05
- Completion
- 2013-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BESIGLIPTIN | Small molecule | 50 mg | — |
| Subject | BESIGLIPTIN | Small molecule | 100 mg | — |